{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:31Z","timestamp":1789194451680,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00259-018-4234-6","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T15:32:39Z","timestamp":1544715159000},"page":"1092-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study"],"prefix":"10.1007","volume":"46","author":[{"given":"Ravit","family":"Geva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabricio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaline M. C.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"4234_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2010.227","volume":"7","author":"LJ Suva","year":"2011","unstructured":"Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208\u201318.","journal-title":"Nat Rev Endocrinol"},{"key":"4234_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14:177\u201383.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4234_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"4234_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411\u201325.","journal-title":"Nat Rev Cancer"},{"key":"4234_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/pcan.2012.42","volume":"16","author":"M Hagiwara","year":"2013","unstructured":"Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16:23\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4234_CR6","first-page":"3120","volume":"62","author":"G Henriksen","year":"2002","unstructured":"Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120\u20135.","journal-title":"Cancer Res"},{"key":"4234_CR7","first-page":"252","volume":"44","author":"G Henriksen","year":"2003","unstructured":"Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252\u20139.","journal-title":"J Nucl Med"},{"key":"4234_CR8","doi-asserted-by":"publisher","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","volume":"12","author":"OS Bruland","year":"2006","unstructured":"Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s\u20137s.","journal-title":"Clin Cancer Res"},{"key":"4234_CR9","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","volume":"23","author":"MI Suominen","year":"2017","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017;23:4335\u201346.","journal-title":"Clin Cancer Res"},{"key":"4234_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/jnci\/djt116","volume":"105","author":"MI Suominen","year":"2013","unstructured":"Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013;105:908\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"4234_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"4234_CR12","unstructured":"Xofigo (radium Ra 223 dichloride) injection, for intravenous use [package insert] Wayne, NJ; Bayer Healthcare Pharmaceuticals Inc; May 2013."},{"key":"4234_CR13","doi-asserted-by":"publisher","first-page":"Abstract 5075","DOI":"10.1200\/JCO.2016.34.15_suppl.5075","volume":"34","author":"MJ Morris","year":"2016","unstructured":"Morris MJ, Loriot Y, Sweeney C, Fizazi K, Ryan CJ, Shevrin DH, et al. Updated results: a phase I\/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. J Clin Oncol. 2016;34:Abstract 5075.","journal-title":"J Clin Oncol"},{"key":"4234_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1634\/theoncologist.10-9-665","volume":"10","author":"A Eniu","year":"2005","unstructured":"Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005;10:665\u201385.","journal-title":"Oncologist"},{"key":"4234_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","volume":"83","author":"I Ringel","year":"1991","unstructured":"Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst. 1991;83:288\u201391.","journal-title":"J Natl Cancer Inst"},{"key":"4234_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","volume":"18","author":"R Paridaens","year":"2000","unstructured":"Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol. 2000;18:724\u201333.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-4234-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T19:08:07Z","timestamp":1576177687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-4234-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4234"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-4234-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R. Geva has been paid honoraria by MSD, BMS, Janssen, Lilly, Novartis, Bayer, Medison, Roche, Pfizer, Merck, and Takeda, paid for a consulting or advisory role by MSD, and had travel, accommodations, or other expenses paid for by BMS. J. Lopez has been paid for a consulting or advisory role by Eisai, paid for participation in a speakers\u2019 bureau for Roche, conducted research funded by Roche-Genentech, Merck, Basilea, Merck-Serono, Vertex, Bayer, Eisai, AstraZeneca, GSK, and Genmab, and had travel, accommodations, or other expenses paid for by Basilea and Roche-Genentech. S. Danson has been paid for a consulting or advisory role by Incanthera, paid for participation in a speakers\u2019 bureau by Amgen and BMS, conducted research funded by multiple clinical trials including Bayer, Amgen, BMS, MSD, Boehringer Ingelheim, Eli Lilly, and Sierra, and had travel, accommodations, or other expenses paid for by Amgen, MSD, and BMS. H. Joensuu has been employed by Orion Pharma, has owned stock or held an ownership interest in Orion Pharma, Faron Pharmaceuticals, and Sartar Therapeutics, has been paid for a consulting or advisory role by Orion Pharma, Neutron Therapeutics, and holds patents or has patents pending, receives royalties, or has other intellectual property interests with Sartar Therapeutics. A. Peer has been paid for a consulting or advisory role by Roche, MSD, Novartis, Pfizer, BMS, Bayer, Astellas, Janssen, and AstraZeneca. F. Souza has been employed and paid honoraria by, conducted research funded by, and had travel, accommodations, and expenses paid for by Bayer. K. M. C. Pereira has been employed by Bayer. R. Perets has been employed by and paid for a consulting or advisory role by Musli Thyropeutics and has been paid honoraria by and owned stock or held an ownership interest in BMS. No potential conflicts of interest were disclosed by the other author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}